Side effects may occur with any kind of cancer therapy. When the cardiovascular and/or respiratory systems are involved, the effects may cause significant morbidity and mortality. Pharmacologic immunosuppression may functionally impair the immunosurveillance of recipients, increasing the risk of cancer development. The majority of these cancers are pathogenically related to oncogenic viruses (e.g HHV8, EBV, HPV), whose control by host immune system is impaired in the transplant setting. In this webinar, we will discuss the pathology of potentially life-threatening cardiovascular and pulmonary complications of cancer therapies. We will also discuss the role oncogenic viruses play in the development of cancer in allografts. Finally, an expert oncologist will discuss the challenging task of diagnosing and managing neoplasia in solid organ transplant patients.

The session will be divided in three parts comprising 15-minute lectures each followed by around five minutes of questions and answers.
 

Scientific Program

Moderators:
Gregory Fishbein, MD, UCLA, Los Angeles, CA USA
Federica Pezzuto, MD, PhD, University of Padova, Italy, Padova, Italy

Cardiopulmonary Failure as a Sequela of Cancer Therapies
Robert Padera, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA

De Novo Viral Related Malignancies in Lung and Heart Allografts
Katharina Wassilew, MD, MHBA, Royal Brompton Hospital, London, UK

Challenges in the Diagnosis and Management of Cancer in the Post-Transplant Patient
Wanxing Chai-Ho, MD, UCLA, Los Angels, CA USA
 

Continuing Education Information

There will be no continuing education available for this webinar.